Featured Research

from universities, journals, and other organizations

Health Canada's fast-tracked drug approvals can put public at risk, experts say

Date:
October 8, 2012
Source:
York University
Summary:
Drugs streamed into Health Canada's 180-day priority review process are more likely to be withdrawn from the market or earn a serious safety warning than those that undergo the 300-day standard review, new research shows. After accounting for other variables which may have caused this variation, the study concludes that the difference is likely due to the faster review time missing serious safety issues.

Drugs streamed into Health Canada's accelerated review process are more likely to be withdrawn from the market or earn a serious safety warning than those that undergo the standard review, according to a recent paper out of York University.

The study, published online by the Archives of Internal Medicine on Oct. 8, is the first of its kind undertaken in Canada. It tracked a total of 434 new active substances (NASs) approved by Health Canada between 1995 and 2010, examining how many subsequently acquired either serious safety warnings or had to be withdrawn from the market for safety reasons. The NASs were then compared to see whether a difference in safety existed between those that had gone through Health Canada's standard 300 day review period vs. the 180 day priority process.

"I found that drugs that went through the standard process had a 1 in 5 chance of either having a serious safety warning issued or being withdrawn from the market for being unsafe," says study author Dr. Joel Lexchin, Professor in York's Faculty of Health. "However, if the drug goes through the priority process, it has a greater than 1 in 3 chance of having the same outcome."

Though some drugs are moved into the priority process because they provide major therapeutic advances for serious illnesses, such as cancer, HIV/AIDS, and multiple sclerosis, and thus may be put through with a lower benefit to harm safety ratio, Lexchin found that the types of drugs in the priority category, and the types of diseases they treated, did not account for the difference in safety issues.

"Even drugs that provided no major therapeutic advances were still more likely to acquire serious safety issues if they were put through the priority review," says Lexchin. "This indicates that the difference is likely due to the faster review missing serious safety issues."

The study concludes that new products that offer major therapeutic advantages should be embraced, even with the significant gaps that exist about their safety, but because most NASs do not fall into this category, clinicians and patients should be using these drugs very cautiously.


Story Source:

The above story is based on materials provided by York University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Joel Lexchin. New Drugs and SafetyWhat Happened to New Active Substances Approved in Canada Between 1995 and 2010?. Archives of Internal Medicine, 2012; 1 DOI: 10.1001/archinternmed.2012.4444

Cite This Page:

York University. "Health Canada's fast-tracked drug approvals can put public at risk, experts say." ScienceDaily. ScienceDaily, 8 October 2012. <www.sciencedaily.com/releases/2012/10/121008161852.htm>.
York University. (2012, October 8). Health Canada's fast-tracked drug approvals can put public at risk, experts say. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2012/10/121008161852.htm
York University. "Health Canada's fast-tracked drug approvals can put public at risk, experts say." ScienceDaily. www.sciencedaily.com/releases/2012/10/121008161852.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins